Table 5 Correlation between clinical outcomes and pathogens identified in neonatal gastric fluid
From: Ureaplasma in neonatal gastric fluid contributing to bronchopulmonary dysplasia
Group 1 | Group 2 | P value | Group 3 | P value | Group 4 | P value | |
|---|---|---|---|---|---|---|---|
U-/O-, n = 74 | U+/O-, n = 26 | U+/O+, n = 7 | U-/O+, n = 14 | ||||
BPD, n (%) | 25 (33.8%) | 16 (61.5%) | 0.02 | 4 (57.1%) | n.s | 7 (50.0%) | n.s |
--Moderate | 2/25 (8.0%) | 4/16 (25.0%) | 0/4 (0%) | 2/14 (14.2%) | |||
--Severe | 7/25 (28.0%) | 7/16 (43.8%) | 3/7 (42.8%) | 2/14 (14.2%) | |||
RDS, n (%) | 57 (77.0%) | 20 (76.9%) | n.s | 6 (85.7%) | n.s | 11 (78.5%) | n.s |
-- RDS ≥ grade 3 | 11 (14.8%) | 2 (7.6%) | 5 (71.4%) | 4 (28.5%) | |||
NEC, n (%) | 7 (9.5%) | 2 (7.7%) | n.s | 2 (28.5%) | n.s | 0 (0%) | n.s |
ROP, n (%) | 14 (18.9%) | 6 (23.1%) | n.s | 1 (14.3%) | n.s | 6 (42.9%) | n.s |
ICH, n (%) | 14 (18.9%) | 3 (11.5%) | n.s | 2 (28.6%) | n.s | 4 (28.6%) | n.s |
Sepsis, n (%) | 1 (1.4%) | 0 (0%) | n.s | 2 (28.6%) | 0.019 | 5 (35.7%) | < 0.001 |
PDA requiring treatment, n (%) | 4 (5.4%) | 2 (7.7%) | n.s | 0/7 (0%) | n.s | 0 (0%) | n.s |
Mortality, n (%) | 6 (8.1%) | 2 (7.7%) | n.s | 4 (57.1%) | < 0.001 | 2 (14.3%) | n.s |